ReviewRadiology2021
CT of Post-Acute Lung Complications of COVID-19.
Review in Radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 209 citations in OpenAlex.
- Chest CT-detected pulmonary nodules across the COVID-19 pandemic in Guangzhou, China: a regression discontinuity-in-time study, 2013-2023.Translational lung cancer research · 2026Article
- Beneficial Effect of COVID-19 Vaccination on Decreased Pulmonary Vascular and Airway Volumes of Patients with Long-COVID Syndrome.Medical sciences (Basel, Switzerland) · 2026Article
- Review
- Seawater drowning induced acute lung injury: new insights from novel mouse models and micro-CT imaging.Open medicine (Warsaw, Poland) · 2026Article
- The immune dysregulation of fibrosis: insights into immune-fibrotic crosstalk and potential therapeutic targets.Frontiers in immunology · 2026Review
- Spontaneous Pneumothorax: A Review of Underlying Etiologies and Diagnostic Imaging Modalities.Tomography (Ann Arbor, Mich.) · 2025Review
- Revisiting the monocrotaline-treated rat as a model of inflammatory lung disease: COVID-19 and future pandemic threats?Animal models and experimental medicine · 2025Review
- Review
- Hematologic and Computed Tomography Features for Discriminating COVID-19 From Non-COVID-19 Pneumonia.Archives of Razi Institute · 2025Article
- Long-Term Pulmonary Function in Healthcare Workers: A Spirometric Evaluation Three Years Post-COVID-19 Pandemic.Biomedicines · 2025Article
- Four-year respiratory consequences of COVID-19 related pneumonia: a longitudinal cohort study.BMC pulmonary medicine · 2025Article
- Long-Term Effects of COVID-19: Analysis of Imaging Findings in Patients Evaluated by Computed Tomography from 2020 to 2024.Tomography (Ann Arbor, Mich.) · 2025Article
- Serum Lactate Dehydrogenase Levels Reflect the Lung Injury Extension in COVID-19 Patients at Hospital Admission.Immunity, inflammation and disease · 2025Article
- Presence and Evolution of Radiological Changes at 6 and 12 Months After COVID-19 Pneumonia and Their Risk Factors.Medicina (Kaunas, Lithuania) · 2025Article
- Retrospective cohort analysis on predicting pulmonary fibrosis in elderly SARS-CoV-2-infected patients.Frontiers in cellular and infection microbiology · 2025Article
- Clinical and CT image features for survival prediction in severe pneumonia during the SARS-CoV-2 Omicron wave.Frontiers in medicine · 2025Article
- The effect and safety of small-molecule antiviral drugs on long prognosis of post-COVID-19 pulmonary fibrosis: a real-world study in China.Frontiers in microbiology · 2025Article
- Investigation and analysis of rehabilitation therapists' current situation in Hunan province after the COVID-19 epidemic: a cross-sectional study.Frontiers in rehabilitation sciences · 2025Article
- Exercise interventions for pulmonary function impairment: rehabilitation strategies from the acute phase to long-term sequelae.Frontiers in physiology · 2025Review
- Identifying central symptom clusters and correlates among post-COVID-19 pulmonary fibrosis patients: a network analysis.Frontiers in medicine · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acute course of COVID-19 is variable and ranges from asymptomatic infection to fulminant respiratory failure. Patients recovering from COVID-19 can have persistent symptoms and CT abnormalities of variable severity. At 3 months after acute infection, a subset of patients will have CT abnormalities that include ground-glass opacity (GGO) and subpleural bands with concomitant pulmonary function abnormalities. At 6 months after acute infection, some patients have persistent CT changes to include the resolution of GGOs seen in the early recovery phase and the persistence or development of changes suggestive of fibrosis, such as reticulation with or without parenchymal distortion. The etiology of lung disease after COVID-19 may be a sequela of prolonged mechanical ventilation, COVID-19-induced acute respiratory distress syndrome (ARDS), or direct injury from the virus. Predictors of lung disease after COVID-19 include need for intensive care unit admission, mechanical ventilation, higher inflammatory markers, longer hospital stay, and a diagnosis of ARDS. Treatments of lung disease after COVID-19 are being investigated, including the potential of antifibrotic agents for prevention of lung fibrosis after COVID-19. Future research is needed to determine the long-term persistence of lung disease after COVID-19, its impact on patients, and methods to either prevent or treat it. © RSNA, 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.